Skip to main content

Stefan Molyneux, Part Two



Molyneux's most sustained effort at systematic philosophy is the book Universally Preferable Behavior (2007).

Upon publication, it was the object of a memorable take-down by David Gordon, a senior fellow at the Ludwig von Mises Institute.

Here is that review: https://mises.org/library/molyneux-problem

One incidental fact: Gordon's review is headlined "The Molyneux Problem," which is a sidelong reference to another Molyneux from a long time ago.

It was in 1688 that an Irishman, William Molyneux, wrote to the English philosopher John Locke asking him about an issue in the psychology of perception.  He asked whether a man who has been born blind, and who has learned to distinguish between a sphere and a cube by touch, would be able to distinguish the sphere from the cube if he did gain sight in the course of his adult life, by sight alone. This is the original Molyneux Problem.

Why is the historical pun relevant to the book? Gordon's view of Molyneux is that of someone who learned of certain philosophical issues late in life, and who quickly convinced himself he had solved them. Perhaps the (formerly) blind man sees shapes for the first time and wrongly believes he knows which one is which and, blissfully unaware of his own ignorance, doesn't bother to check this ought through tactile examination.

Gordon's review (combined with my own slight exposure to Molyneux's superficial philosophizing in an audio of a lecture of his to which I listened a couple of years back) has been for me sufficiently persuasive that I've never moved on to the book.

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…